FY2024 EPS Estimates for AC Immune Increased by Analyst

AC Immune SA (NASDAQ:ACIU - Free Report) - Leerink Partnrs lifted their FY2024 EPS estimates for shares of AC Immune in a report issued on Tuesday, November 5th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of ($0.60) per share for the year, up from their prior estimate of ($0.81). The consensus estimate for AC Immune's current full-year earnings is ($0.89) per share. Leerink Partnrs also issued estimates for AC Immune's Q4 2024 earnings at ($0.20) EPS, FY2025 earnings at ($0.87) EPS and FY2028 earnings at $0.00 EPS.

Several other equities research analysts have also commented on the stock. HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of AC Immune in a research note on Wednesday. StockNews.com lowered shares of AC Immune from a "buy" rating to a "hold" rating in a research note on Tuesday, October 1st.

AC Immune Price Performance

NASDAQ:ACIU traded down $0.07 during mid-day trading on Friday, hitting $3.20. 74,226 shares of the company's stock were exchanged, compared to its average volume of 346,172. AC Immune has a one year low of $2.25 and a one year high of $5.14. The business has a fifty day moving average price of $3.27 and a 200 day moving average price of $3.45. The company has a market cap of $316.61 million, a PE ratio of -4.44 and a beta of 1.28.

AC Immune (NASDAQ:ACIU - Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of $0.42 by ($0.67). The firm had revenue of $0.76 million for the quarter, compared to analysts' expectations of $91.60 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Lazard Asset Management LLC bought a new position in shares of AC Immune in the first quarter worth approximately $30,000. BNP Paribas Financial Markets lifted its stake in shares of AC Immune by 315.6% in the first quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company's stock worth $33,000 after buying an additional 8,423 shares in the last quarter. Silverberg Bernstein Capital Management LLC purchased a new position in shares of AC Immune during the second quarter valued at approximately $40,000. Vanguard Capital Wealth Advisors purchased a new position in shares of AC Immune during the second quarter valued at approximately $56,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of AC Immune by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company's stock valued at $72,000 after purchasing an additional 7,400 shares during the last quarter. Institutional investors own 51.36% of the company's stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.